Viral Hepatitis

Infectious Diseases
3
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vir Biotechnology
Vir BiotechnologyCA - San Francisco
3 programs
1
2
TobevibartPhase 31 trial
TobevibartPhase 31 trial
TobevibartPhase 21 trial
Active Trials
NCT07142811Active Not RecruitingEst. Jul 2030
NCT07128550RecruitingEst. Jul 2031
NCT06903338Active Not RecruitingEst. May 2031

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
Vir BiotechnologyTobevibart
Vir BiotechnologyTobevibart
Vir BiotechnologyTobevibart

Clinical Trials (3)

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Start: Jul 2025Est. completion: Jul 2031
Phase 3Recruiting

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Start: Mar 2025Est. completion: May 2031
Phase 3Active Not Recruiting

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Start: Aug 2025Est. completion: Jul 2030
Phase 2Active Not Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space